Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLaurie H. SehnSYSung‐Soo YoonNGNorma C. Gutiérrez

Discussion

Loading...

Member takes

Overview

Pivotal trial demonstrates 74% overall response rate in patients with relapsed follicular lymphoma, suggesting effective treatment with manageable adverse events.

Key Points

  • Complete response achieved in 63% of patients, demonstrating a significant treatment effect.
  • The overall response rate was 74%, with durable remissions reflected in median progression-free survival of 18.5 months.
  • Analysis of a pivotal Phase II study followed 94 patients receiving subcutaneous mosunetuzumab for relapsed follicular lymphoma.
  • Management of cytokine release syndrome and injection site reactions indicates a favorable safety profile for outpatient treatment.

Cite This Study

Sehn et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db57https://doi.org/10.1182/blood-2025-5353
View Full Paper
Ask AI
Bookmark
Share